Patient P-01688

Synthetic patientNBL-101 · Day 113 · 55–64 · F · baseline S01Steering view · 3D Open companion preview

Therapy response

Unstable

Tolerance

Improving

GI state

Improving

Inflammatory state

Deteriorating

Nutritional resilience

Improving

Discontinuation risk

47%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S01
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −18% vs expected — Dietary Support Protocol NP-02
Day 44 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 48 Tolerance state changed — Unstable → Improving
Day 55 GI-04 recommended — GI Support Protocol GI-04
Day 56 Patient accepted — Started GI-04 in the companion
Day 64 GI symptom burden −22% vs expected — GI Support Protocol GI-04
Day 70 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 44.

Primary contributors, last 14 days

GI instability-6
Inflammatory activity+6
Nutritional resilience+6
Toxicity-5
Treatment adherence-4

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −18%
GI Support Protocol GI-04Day 55
Result: symptom burden −22%

LIFE OS recommendation

Dosing / Timing Recommendation DT-01

75%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 5 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

41.3/100

stable · -1.6 vs previous 14 d

Toxicity

Blood

36.6/100

stable · -0.1 vs previous 14 d

Sleep quality

Wearable

35.7/100

improving · +6.2 vs previous 14 d

Energy level

Daily log

4.3/10

improving · +0.1 vs previous 14 d

Stress level

Daily log

5.6/10

stable · +0.1 vs previous 14 d

Steps

Wearable

3,753

stable · -9 vs previous 14 d

Adherence

Companion

49.5 %

improving · +3.1 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading towards restoration · 37 from the failing basin, 52 from restoration.

Good elements to keep

GI Support Protocol GI-04
intervention · steering +36.1
Dietary Support Protocol NP-02
intervention · steering +28.4
Daily walks resumed
perturbation · steering +3.3

Main detractors to watch

Low butyrate capacity
hidden · steering -17.5
Dietary fat load
perturbation · steering -12.6
FUT2 non-secretor
hidden · steering -10.6
Insoluble fibre
perturbation · steering -8.1
Dietary fat load
detractor · GI +6.5 next day
Histamine load
detractor · GI +4.5 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+6.5detractor · 95%
Histamine load
+4.5detractor · 95%
Insoluble fibre
+4.5detractor · 95%
Alcohol
+4detractor · 95%
Simple carbohydrates
+3.1no signal · 54%
Spicy / capsaicin
+0.7no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 29/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 47
- WearableHRV 26 ms, trending down
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
Autonomic recovery ↑20
- Wearable3,753 steps/day

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.8 · butyrate capacity 29/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 25 ms
Sleep: 5.8 h
Steps: 2,787
Resting HR: 73 bpm

Daily log: GI score 41, nutritional resilience 48, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01604	24%	S01	—	—	71
P-01699	28%	S04	GI-04	improved	69
P-01508	24%	S18	—	—	68
P-01509	24%	S17	—	—	68
P-01877	27%	S01	CR-01	improved	67
P-01629	25%	S19	—	—	66
P-01714	30%	S14	GI-04	improved	66
P-01858	30%	S14	NP-02	improved	65
P-01317	24%	S19	—	—	65
P-01643	26%	S17	—	—	65
P-01417	28%	S14	GI-04	improved	65
P-01511	30%	S14	GI-04	improved	65